A Randomized Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
Latest Information Update: 29 Jul 2025
At a glance
- Drugs BCD 261 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Biocad
Most Recent Events
- 29 Jul 2025 New trial record